Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 10 art units • 14 examiners • 0 of 15 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. maintains 15 pending office actions within the Biotechnology & Pharmaceuticals technology area. These legal matters are currently being reviewed by 14 distinct examiners. The ratio of 15 pending actions to 14 examiners indicates a prosecution process where almost every matter is handled by a different individual. This approach can lead to different examiner experiences across the portfolio.
The company's patent applications are distributed across 10 distinct art units. The presence of 10 art units for 15 pending actions suggests that the company's pharmaceutical research covers many specialized technical classifications. BRISTOL, LYNN ANNE is the busiest examiner for this portfolio, managing 2 pending office actions. While Bristol is the busiest, the 2 pending actions represent only a portion of the 15 total actions. This distribution ensures that the company's intellectual property strategy is spread across many examination groups at the patent office.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (13%) |
| §112 only | 5 (33%) |
| Double-patenting + other | 1 (7%) |
| Multi-statute (no §101) | 7 (47%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 2 | 63.4% | +39.8% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
| BORI, IBRAHIM D | 1 | 43.8% | +38.9% |
| MELCHIOR, JAMES RYLAND | 1 | 63.0% | +38.5% |
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
| PRIEST, JESSICA MARIE | 1 | — | — |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712407 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | HABTE, KAHSAY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | LEE, CHIHYI NMN | 24d overdue |
| 18849031 | CRYSTAL OF FUSED TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | COLEMAN, BRENDA LIBBY | — |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | NATARAJAN, MEERA | — |
| 18690198 | COMBINED PHARMACEUTICAL COMPOSITION OF CDK4/6 INHIBITOR AND AROMATASE INHIBITOR | BORI, IBRAHIM D | — |
| 18578850 | COMBINATION DRUG FOR TREATMENT OF GASTRIC CARCINOMA AND/OR ESOPHAGOGASTRIC JUNCTION CANCER | MELCHIOR, JAMES RYLAND | — |
| 18569115 | ANTI-IL-36R ANTIBODY AND USE THEREOF | PETERS, ALEC JON | — |
| 18007012 | NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | LEE, CHIHYI NMN | 24d overdue |
| 17922230 | ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF | BRISTOL, LYNN ANNE | 24d overdue |
| 18849031 | CRYSTAL OF FUSED TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | COLEMAN, BRENDA LIBBY | — |
| 18703668 | ANTIBODY BINDING TO C-MET AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | NATARAJAN, MEERA | — |
| 18690198 | COMBINED PHARMACEUTICAL COMPOSITION OF CDK4/6 INHIBITOR AND AROMATASE INHIBITOR | BORI, IBRAHIM D | — |
| 18578850 | COMBINATION DRUG FOR TREATMENT OF GASTRIC CARCINOMA AND/OR ESOPHAGOGASTRIC JUNCTION CANCER | MELCHIOR, JAMES RYLAND | — |
| 18569115 | ANTI-IL-36R ANTIBODY AND USE THEREOF | PETERS, ALEC JON | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1646 | 1 |
| 1629 | 1 |
| 1645 | 1 |
| 1642 | 1 |
| 1628 | 1 |
| 1626 | 1 |
| 1674 | 1 |
| 1647 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849031 | CRYSTAL OF FUSED TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | COLEMAN, BRENDA LIBBY | — | §103§112Other | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18712407 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | HABTE, KAHSAY | — | §112 | Non-Final OA | — | Pending | May 22, 2024 |
| 18703668 | ANTIBODY BINDING TO C-MET AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | 1646 | §112Other | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | NATARAJAN, MEERA | — | §102§103§112 | Non-Final OA | — | Pending | Mar 11, 2024 |
| 18690198 | COMBINED PHARMACEUTICAL COMPOSITION OF CDK4/6 INHIBITOR AND AROMATASE INHIBITOR | BORI, IBRAHIM D | 1629 | §103§112Other | Final Rejection | — | Pending | Mar 07, 2024 |
| 18578850 | COMBINATION DRUG FOR TREATMENT OF GASTRIC CARCINOMA AND/OR ESOPHAGOGASTRIC JUNCTION CANCER | MELCHIOR, JAMES RYLAND | 1645 | §102§103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18569115 | ANTI-IL-36R ANTIBODY AND USE THEREOF | PETERS, ALEC JON | — | §102§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18285511 | MULTI-SPECIFIC ANTIBODY TARGETING BCMA | PRIEST, JESSICA MARIE | 1642 | §112DP | Non-Final OA | — | Pending | Oct 04, 2023 |
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | LEE, CHIHYI NMN | 1628 | §102§103§112 | Final Rejection | 24d overdue | Pending | Jul 27, 2023 |
| 18253846 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | CHICKS, ASHLI ARIANA | 1626 | §103 | Non-Final OA | 147d overdue | Pending | May 22, 2023 |
| 18019612 | COMBINED MEDICATION FOR TREATING SOFT TISSUE SARCOMA | KAUFMAN, CLAIRE M | 1674 | §103Other | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18007012 | NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION | BRISTOL, LYNN ANNE | 1643 | §103§112 | Non-Final OA | — | Pending | Jan 26, 2023 |
| 17924613 | ST2 ANTIGEN BINDING PROTEIN | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | — | Pending | Nov 10, 2022 |
| 17922230 | ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 24d overdue | Pending | Oct 28, 2022 |
| 17792282 | PHARMACEUTICAL COMPOSITION OF TRICYCLIC PDE3/PDE4 DUAL INHIBITOR COMPOUND | HUANG, GIGI GEORGIANA | 1613 | §112 | Non-Final OA | 14d | Pending | Jul 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial